SLRN240920P5000
- 0.69
- 0.000.00%
Acelyrin Newsroom
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
Acelyrin Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Acelyrin, Lowers Price Target to $6
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6
ACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash Runway
HC Wainwright & Co. Downgrades Acelyrin to Neutral, Lowers Price Target to $6
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Acelyrin Analyst Ratings
Piper Sandler Maintains Overweight on Acelyrin, Lowers Price Target to $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Piper Sandler Keeps Their Buy Rating on ACELYRIN, INC. (SLRN)
ACELYRIN, INC. Maintains Hold Rating Amidst Mixed Clinical Results and Competitive Market Challenges
Buy Rating Affirmed: Strategic Focus and Promising Pipeline of ACELYRIN, INC.
Acelyrin Analyst Ratings
Wells Fargo Upgrades ACELYRIN to Overweight From Equalweight, Price Target at $13
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Arrowhead Pharmaceuticals (ARWR) and NovoCure (NVCR)
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
HC Wainwright & Co. : The Acelyrin (SLRN.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $16.00 to $18.00.
Acelyrin Analyst Ratings
HC Wainwright & Co. Maintains Buy on Acelyrin, Raises Price Target to $18